Media formats available:
Recommended
- Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglyceridesIntegrating EPA-based therapy in the management of residual CV risk
Prof. Ph. Gabriel Steg, MD
- Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglyceridesWhat is the evidence of EPA-based therapy for CV prevention?
Prof. Lale Tokgözoğlu, MD